Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Grows By 5.1%

Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 3,320,000 shares, an increase of 5.1% from the January 31st total of 3,160,000 shares. Based on an average daily volume of 382,100 shares, the short-interest ratio is presently 8.7 days.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 59.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 279 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. Belpointe Asset Management LLC bought a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $46,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $49,000. Wipfli Financial Advisors LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $53,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $54,000.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. SVB Leerink reduced their price target on Ascendis Pharma A/S from $168.00 to $148.00 and set an “outperform” rating on the stock in a report on Monday, November 14th. Wells Fargo & Company boosted their price target on Ascendis Pharma A/S from $169.00 to $177.00 and gave the company an “overweight” rating in a report on Tuesday, January 3rd. Morgan Stanley upped their target price on Ascendis Pharma A/S from $148.00 to $151.00 and gave the stock an “overweight” rating in a report on Friday, February 17th. Wedbush upped their target price on Ascendis Pharma A/S from $151.00 to $164.00 and gave the stock an “outperform” rating in a report on Monday, November 14th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $130.00 target price on shares of Ascendis Pharma A/S in a report on Friday, February 17th. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.55.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $113.56 on Tuesday. The company has a quick ratio of 4.63, a current ratio of 5.39 and a debt-to-equity ratio of 1.83. The company has a market capitalization of $6.48 billion, a P/E ratio of -10.47 and a beta of 0.55. The stock’s 50 day moving average is $117.22 and its 200 day moving average is $112.43. Ascendis Pharma A/S has a twelve month low of $61.58 and a twelve month high of $134.52.

Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) last posted its quarterly earnings results on Thursday, February 16th. The biotechnology company reported ($3.78) earnings per share for the quarter, missing the consensus estimate of ($2.50) by ($1.28). The company had revenue of $23.38 million during the quarter, compared to analysts’ expectations of $20.31 million. Ascendis Pharma A/S had a negative return on equity of 114.11% and a negative net margin of 1,149.60%. On average, equities research analysts predict that Ascendis Pharma A/S will post -10.79 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.